We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Insulet (PODD - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.48 per share, reflecting an increase of 28.7% compared to the same period last year. Revenues are forecasted to be $767.33 million, representing a year-over-year increase of 28.4%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Insulet metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total Omnipod' at $765.48 million. The estimate suggests a change of +30.7% year over year.
The combined assessment of analysts suggests that 'Revenue- Drug Delivery' will likely reach $0.97 million. The estimate indicates a change of -91.8% from the prior-year quarter.
The consensus estimate for 'Revenue- International Omnipod' stands at $209.64 million. The estimate indicates a year-over-year change of +47.6%.
According to the collective judgment of analysts, 'Revenue- U.S. Omnipod' should come in at $555.84 million. The estimate indicates a year-over-year change of +25.3%.
Over the past month, Insulet shares have recorded returns of -11.3% versus the Zacks S&P 500 composite's -0.3% change. Based on its Zacks Rank #4 (Sell), PODD will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS
In its upcoming report, Insulet (PODD - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.48 per share, reflecting an increase of 28.7% compared to the same period last year. Revenues are forecasted to be $767.33 million, representing a year-over-year increase of 28.4%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Insulet metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total Omnipod' at $765.48 million. The estimate suggests a change of +30.7% year over year.
The combined assessment of analysts suggests that 'Revenue- Drug Delivery' will likely reach $0.97 million. The estimate indicates a change of -91.8% from the prior-year quarter.
The consensus estimate for 'Revenue- International Omnipod' stands at $209.64 million. The estimate indicates a year-over-year change of +47.6%.
According to the collective judgment of analysts, 'Revenue- U.S. Omnipod' should come in at $555.84 million. The estimate indicates a year-over-year change of +25.3%.
View all Key Company Metrics for Insulet here>>>Over the past month, Insulet shares have recorded returns of -11.3% versus the Zacks S&P 500 composite's -0.3% change. Based on its Zacks Rank #4 (Sell), PODD will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .